Paediatric and Maternal Schistosomiasis: Shifting the Paradigms

Amaya L. Bustinduy[a,*], J. Russell Stothard[b] and Jennifer F. Friedman [c]

[a] Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK; [b] Department of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK; [c] Center for International Health Research, 55 Calverick Street, Suite 101, Providence, RI 02903, USA

[*] Corresponding address. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

E-mail: Amaya.Bustinduy@lshtm.ac.uk

Abstract

Background: In endemic area, schistosomiasis causes both overt and subclinical disease in young children and their mothers, as well as in returned travellers.

Sources of data: Key recently published literature.

Areas of agreement: An action plan for paediatric schistosomiasis and female genital schistosomiasis (FGS) is needed with expanded access to praziquantel (PZQ) required.

Areas of controversy: Schistosomiasis-related morbidity is underappreciated. Present and future demand for PZQ treatment is bottlenecked, imbalanced and inequitable. Current dosing, treatment algorithms and access plans are sub-optimal with treatment stalled during pregnancy in antenatal clinics.

Growing points: Raised dosing of PZQ (> 40 mg/kg) is being explored in young children. Surveillance of female genital schistosomiasis (FGS) is increasing. Use of PZQ in pregnancy is safe and guidelines for preventive chemotherapy are being revised in morbidity- and transmission-control settings.

Areas timely for developing research: Shifting focus of population-level control to individual-case management. Detection and prevention of FGS integrating PZQ delivery in child and women health services and antenatal clinics. Feasibility studies assessing alternative and expanded access to PZQ treatment to at-risk children and mothers and pregnant women.

Key words: praziquantel, PZQ, preventive chemotherapy, MDA, female genital schistosomiasis, FGS, pregnancy, HIV.

Running head: Paediatric and maternal schistosomiasis

Word count: 3,883

Introduction

Schistosomiasis is a water-borne disabling parasitic disease responsible for over 3.3 million disability adjusted life years (DALY) worldwide. [1] This figure is underestimated and in process of upward revision in more recent burden of disease studies. [2] Over 700 million people are at-risk of acquiring an infection with any of the most relevant *Schistosoma* species and these giving rise to two major clinical syndromes: 1- Intestinal schistosomiasis, caused by *S. mansoni* (South America and sub-Saharan Africa (SSA)) and *S. japonicum* (China, Philippines), and 2- Urogenital schistosomiasis caused by *S. haematobium* (SSA). Of the currently recognised neglected tropical diseases caused by parasitic helminths[3], schistosomiasis can be considered unique as being the sole water-borne parasite able to infect humans by per-cutaneous transmission[4]. Acute schistosomiasis, most commonly asspociated with *S. japonicum*, is an infrequent manifestation of the disease and is also known as 'Katayama fever', clinically presenting as a serum-sickness like syndrome. [5] More common chronic manifestation of all types of schistosomiasis result from egg-deposition in target organs and subsequent fibrosis impairing normal function. Less specific but more widely seen clinical characteristics are those derived from the pro-inflammatory response triggered by the parasite. These affect mostly children that are infected as early as infancy,[6] and include anaemia of inflammation, impaired linear growth, decreased physical fitness and decreased quality of life. [7] Disease recognition is often overlooked and underappreciated, particularly in younger children with early stages of schistosomiasis, as clinical features are shared and masked with other endemic diseases such as malaria. [4] Recognition of all disease stages by low-level skilled health workers is currently lacking and represents a hurdle to increase praziquantel (PZQ) treatment coverage beyond community-based control programmes, the mainstay of schistosomiasis control. A recent schistosomiasis clinical staging algorithm to aid diagnosis in low-resource settings has recently been published. [8]

Without anthelminthic treatment with PZQ, adult schistosomes may live for decades within the host.[9] By contrast, juvenile worms are tolerant to PZQ making this drug an imperfect

treatment tool against acute infection, which is difficult to diagnose unequivocally even with modern biomarkers of infection[10]. On the other hand, as schistosome worms increase in number, pair and mature to lay eggs subsequently through time, the diagnostic patency of chronic schistosomiasis becomes ever more apparent; as does the congruency of a variety of serological, molecular or parasitology methods[11]. Using a selection of these markers it is possible to monitor the efficacy of PZQ treatment[11] for which there are WHO guidelines that measure the proportional reduction of schistosome eggs in excreta before and after treatment. On the whole, the performance of PZQ is adequate according to those WHO standard measures of cure.[12] However, measures of drug efficacy are poorer in younger children[13] and across all ages in high prevalence and transmission environments[14].

Infected and overlooked

Children and mothers in the endemic setting

The endemic transmission landscape of schistosomiasis is typically over-dispersed or focal such that the disease can be very concentrated geographically around a given freshwater habitat, while others nearby may experience no disease at all[15]. In such an area, e.g. a rural village where there this schistosomiasis, the patency of infection varies by age and gender[4]. Using traditional diagnostic methods based on egg-detection the most obvious infected group are children, of either gender, in their late childhood and early adolescence[4]. This has been the 'classic' view of the epidemiology of schistosomiasis in an endemic setting for many years as shown in Figure 1A and discussed by Peter Jordan in this journal some 45 years ago[16]. However since that time, a more extensive knowledge and appreciation of schistosomiasis has been developed, now seen as a complex disease that may or may not coincide with present egg-patent infection.[2] The traditional view based on egg-patency in the excreta gave rise to the commonly held assumption that only heavy egg-patent infections were important and those of light or moderate could be ignored[17]. This view is largely incorrect; if alternative diagnostic methods are used such as serology or biomarkers, schistosomiasis is much more pervasive in mothers and young children than previously thought[18]. Using a combination of

diagnostic assays has helped to better reveal the burden of disease in pre-school-aged children and their mothers[19]. But it's not only improved diagnostic accuracy for *Schistosoma* detection, morbidity detection methods have also been refined and thus schistosomiasis encompasses not only the chronic manifestations related to end-organ fibrosis (portal hypertension due to periportal fibrosis, bladder polyps and squamous cell carcinoma of the bladder), but it now includes more *functional* morbidities such as anaemia and arrested linear growth that are reversible only if treated early in childhood. The inputs used for the global Burden of Disease 2010 study underestimated the burden of the disability associated with *Schistosoma* infection.[20] These estimates did also not include late effects of the *functional* morbidities, of which growth stunting and cognitive impairment, infertility, dyspareunia and genital disease are now widely recognised as schistosomiasis-associated morbidities. Therefore the concept of an asymptomatic disease, historically describing children without overt clinical signs and symptoms, with no obvious chronic manifestations, can no longer be accepted. [2]

Figure 1: A schematic of (**A**) prevalence by age inferred by egg-count versus serology across an endemic population (i.e. in mothers and their children's) and (**B**) visual detection of antibodies to soluble eggs antigen (SEA) in mothers (M) and children (C) from lakeshore village on Lake Albert, Uganda. Positive (+) and negative (-) controls indicated.



There is an essential environmental transmission dynamic, as part of the schistosome lifecycle, which is determined by the immediate presence of permissive freshwater snail hosts and by unsafe water contact activities undertaken by the surrounding community, albeit from local or visiting people. In principle, water contact can be broken down into two partially related components, contamination- and exposure-related activities[21]. The transmission epidemiology of schistosomiasis is intricately interwoven with the daily need for water as part of socio-economic development and environmental hygiene. Until recently, as younger children are often not directly seen in water, it was thought that their risk of infection was low and largely in accordance with a low prevalence of egg-patent infection. However, this appraisal was overturned as it is largely by passive water contact, such as *being* bathed in water collected by the mother, often away from view within the homestead, that infants becomes first infected. Such infections are best detected by serological methods. Figure 1B and data from novel studies using global position system data suggest the levels of unsafe water contact of infants and pre-school-aged children can be alarmingly high[18, 22]. Furthermore, there is increasing concern about the importance of maternal schistosomiasis[23] such that the disease should be tackled simultaneously in both child and mother.

Children and mothers within travel medicine

Schistosomiasis is also a travel related disease for those that visit disease endemic locations and knowingly or unknowingly undertake unsafe water contact activities. In the largest returned traveller cohort published in the UK, the most common presenting symptom was haematuria, related to urogenital schistosomiasis and almost half of the patients had eosinophilia. [24] A major difference in travel-related schistosomiasis is the age of the first infection, typically in adults who have had little, if any, prior exposure to any helminthiasis. This allows use of more general immunological markers of infection e.g. eosinophilia [25]. Similarly, with a detailed travel history, the exact time and duration of most likely exposure can be determined[26], setting aside these rather singular events of the traveller from the inevitable daily routine of those that live in close proximity to unsafe water sources. The disease

spectrum that schistosomiasis also induces in travellers differs, typically with a greater number of cerebrospinal complications, largely owing to ectopic egg laying sites, necessitating advanced diagnostic imagery techniques and clinical management [27].

It is interesting that significant disease can accrue in both young children and women with relatively short durations of exposure and infection[28, 29]. For example, there are numerous case reports of maternal schistosomiasis[30] as well as individual cases where complications have arisen from egg-based lesions within the Fallopian tubes [30]. Schistosomiasis within these patients has been typically detected spuriously, for example, upon surgical encounter rather than upon post-visit screening. In the UK, for example, there is no specific-screening programme for schistosomiasis, and diagnostic tests are only requested when there is clinical suspicion, however, awareness of the disease within general practice settings is typically low. In addition, many of these travellers present with low-intensity infections, and current diagnostics may be too insensitive for detection (egg counts in urine or stool). [24] Serology can not distinguish between acute or chronic infection, and cannot evaluate treatment efficacy due to persistent IgG. New antigen diagnostic tests, the Circulating Anodic Antigen (CAA), secreted across *Schistosoma* species is set to become a useful tool for low-level infections as it can detect as little as one worm pair. [31]

Pregnant travellers have seldom been reported in the literature. A recent retrospective case series from Israel reported adverse foetal outcomes including low birth weight, miscarriages and preterm labour, in pregnant women with schistosomiasis acquired during travel that had not received PZQ at any given time after *Schistosoma* exposure compared to those that had received PZQ during pregnancy and had normal birth outcomes. [29]

It is very plausible that many travellers returning to Europe will have schistosomiasis, which will continue to go undetected until clinical manifestations develop. A good example is the recent epidemic focus of urogenital schistosomiasis in Corsica that caught many general practice surgeries by surprise[32]. The first case of urogenital schistosomiasis caused by infection with *S. haematobium* in Corsica was observed in a 4-year old French child upon

presentation to Toulouse Hospital in March 2014 with a persistent history of haematuria. The father of the child and other relatives from France were also found to have chronic haematuria, pointing towards a then hitherto unknown *S. haematobium* transmission focus on the island. Since then there has been a concerted effort to describe and curtail the disease which has raised several concerns unique to this European setting and tourist destination[32].

Focus on female genital schistosomiasis (FGS)

FGS is likely the most underestimated gynaecological disorder in the tropics. It manifests with egg entrapment in the genital mucosa with granuloma formation and neovascular changes. [33] Pathognomonic lesions can be visually seen by colposcopy, but this method is costly and requires high level training, frequently absent in endemic areas. A new visual diagnostic FGS pocket atlas is freely available from WHO (http://apps.who.int/iris/handle/10665/180863) and targeted to clinical health-care professionals and aiming to help with the identification of typical cervical lesions. The main limitation of this promising tool is the need for a colposcope to perform the gynaecological examination.

FGS affects women that are or have been infected with *S. haematobium* at any given point in their lives. The exact onset of the lesions is unknown, as it is not ethically permissive to conduct studies in girls that have not had their sexual debut. However genital symptomatology has been linked to *S. haematobium* infection even in pre-pubertal girls, suggesting early onset of FGS [34]The consequences of the diagnostic difficulties for FGS get reflected in the absence of accurate disease burden estimates in *S. haematobium* areas. This is particularly troublesome when there is strong evidence of a fourfold increase in HIV in women with *Schistosoma* infection.[35, 36] The impact of FGS on women's reproductive life is large with strong ties to infertility and subfertility. [30 37] Cervical fibrotic lesions remain largely unchanged months after PZQ treatment given following current recommended single-dose guidelines. [38] This distressing reality highlights the importance of early treatment to prevent established fibrotic morbidity.

Current control of schistosomiasis with PZQ

The mainstay of schistosomiasis control relies on preventive chemotherapy (PC) with PZQ, a broad spectrum anti-parasitic drug delivered through mass drug administration programmes to school-aged children. Programme regularity relies on background *Schistosoma* spp. prevalence in each endemic country. PZQ is therefore delivered annually (egg-patent prevalence ≥ 50%), every two years (prevalence > 10-50 %) or twice during primary schooling time (prevalence ≥ 10%).[39] In 2012, it was estimated that across the world some 249 million people were in need of regular PC, with 93% of those eligible to be found in sub-Saharan Africa[40]. Only 34% of all eligible school-aged children received PZQ in 2014. [41]

Bottlenecks in global supply and delivery of PZQ

It has been noted across many nations, and also formally reported, that Africa is desperate for PZQ[42], especially given that some 100 million school-aged children are eligible for preventive chemotherapy[43]. Since the development of PZQ in the 1970s, the large-scale production and access plan for this drug has undergone several revisions[44, 45]. The most significant perhaps, was the drop in price from $1.00 USD in 1998 to $ 0.08 USD in 2003 per tablet as then retailed by various pharmaceutical suppliers following from off-patent production[46]. This raw tablet price roughly equates to $ 0.20 USD per 40 mg/kg treatment for a typical school-aged child (i.e. 2.5 tablets) which also enabled simple *per capita* forecasting of its supply as well as likely distribution costs for treatment of school-aged children in school. This has been largely propelled forward by entities like the Schistosomiasis Control Initiative (SCI)[47] operating since 2002. The SCI is a Bill & Melinda Gates Foundation project that has also helped to solidify national actions against other diseases amenable to preventive chemotherapy, for example, against soil-transmitted helminthiasis with co-delivery of albendazole and PZQ to school-aged children using school-based logistical and delivery systems[48].

In 2007, a change in this landscape started to take place upon the first pledged donation *gratis* of PZQ to WHO by Merck-KGaA (Darmstadt, Germany) under their brand name of Cesol™. Over the 2007-2010 period, 20 million PZQ tablets were donated annually,

prequalified by WHO and then shipped in-country to those national control programmes requesting PZQ stocks for use in PC campaigns. Following on the London Declaration on NTDs (http://ntd-coalition.org) in 2012, the Merck-KGaA donation was pledged to expand and up-scale production to a total of 250 M tablets per year by 2020, achieving 103 M donated tablets in 2015.

Since the London Declaration and the Merck-KGaA donation, the production market of PZQ has not been stable, with certain companies reducing or stopping their production. An unforeseen consequence of this is that the donation which is typically ring-fenced for use in school-aged children, is coming under increasing pressure to be used to shore-up access to PZQ in other groups. It is particularly noteworthy that the treatment needs of adults are not factored into the donation, and are largely catered for by Ministries of Health within their procurement of essential drugs.

Expanded access for preventive chemotherapy and treatment to vulnerable populations

Paediatric praziquantel formulation

It is astonishing that the PZQ treatment needs of school-aged children had so long eclipsed those of younger, preschool-aged children who today are considered just as vulnerable, if not more so, than their older counterparts[45]. As recently highlighted, this oversight is concomitant with a general neglect of paediatrics within tropical medicine.[49] From today's perspective, it is unethical to withhold safe medical treatment to those that need it, especially children. Importantly, PZQ has been safely delivered off-license through crushed tablets to hundreds of children under four years of age across different settings.[50] The first pharmacokinetic-pharmacodynamic study in young Ugandan children with *S. mansoni* infection using crushed tablets of PZQ found that raised dosing to 60 mg/kg was favourable to the WHO recommended single dosing of 40 mg/kg[51] which was in contrast to results of a multi-country meta-analysis that only included school-age children[52]. Worryingly, no child achieved bloodstream antigenic clearance based on schistosome circulating anodic antigen (CAA). Given that many of these

children had very high levels of CAA before treatment, to remove this substantial worm burden would require repeated treatments[51].

Current control programmes unduly focus attention on school-aged children that harbour highest intensity egg-patent infection. This is further skewed by the fact that traditional diagnostic methods may miss moderate-light infections that are more commonly seen in the youngest children. [11] This approach downplays the clinical importance of these early infections that require more sensitive diagnostic methods.[53, 54] Ultrasound detectable morbidity is already present in children and lesions responds to higher PZQ doses. [55]

Over the last decade with a greater focus on disease surveillance in children under five years of age, there is a much wider appreciation of their treatment needs[18, 50]. Addressing this, in 2010 WHO held an informal review of the available evidence for treating preschool aged children (PSAC) with schistosomiasis. The recommendations of this meeting concluded that it was possible to use crushed or broken tablets for treatment in the interim until a children-friendly paediatric formulation of PZQ was developed. In response, a public-private-partnership was formed in July 2012 and entitled the paediatric praziquantel consortium (PPC). This was tasked to develop, register and provide an oral dispersible tablet (ODT) for use in future treatment campaigns to supplement the existing Cesol ® 600 mg tablet donation. [56]

Several important decisions first had to be addressed in the development of an appropriate PZQ formulation, its optimal dosing and associated product access plan. Results from ongoing bioavailability studies in the PPC were presented at an additional meeting of the WHO in September 2015 to further assess treatment needs and guidelines for PSAC. [56, 57] The optimal delivery platform to roll-out this new paediatric formulation has yet to be evaluated. As a feasible product delivery plan, PSAC PZQ preventive treatment could be integrated within the ongoing maternal-child health visits as part of the integrated management of childhood illnesses (IMCI), a comprehensive primary health care delivery plan endorsed by WHO. [17]

PZQ in pregnancy

An estimated 40 million women of reproductive age are infected with Schistosomiasis. At the time of its release in 1979, PZQ was never formally studied in pregnant or lactating women and remains a United States Federal Drug Administration pregnancy Class B drug. Its Class B designation was based on numerous animal studies supporting its safety,[58, 59] but a lack of well-controlled trials during human pregnancy. [60]

In 2002, the World Health Organization (WHO) sponsored an "Informal Consultation" on the use of PZQ during pregnancy and lactation. The report emanating from that meeting recommended that all schistosomiasis infected pregnant and lactating women be considered high-risk groups and offered treatment with praziquantel individually or during treatment campaigns.[61-63] This recommendation was reissued in 2006 as part of the WHO's *Guidelines for Preventative Chemotherapy for Helminthiasis* [39] in which it was recommended that pregnant and lactating women be included in mass drug administration (MDA) campaigns. [39]Importantly, at the time of these reports, no randomized controlled trials of praziquantel during human pregnancy had been conducted. Addressing the safety of expanded use, the authors cited demonstrated PZQ's safety in animal models, post-market surveillance data, and PZQ use for the treatment of cysticercosis during pregnancy. With respect to efficacy, the recommendations were based on both demonstrated reversibility of end organ damage and anemia with more frequent treatment, among non-pregnant populations. Many nations did not initially adopt these guidelines citing lack of sufficient safety data from controlled trials.

Praziquantel and human pregnancy: results of two randomized controlled trials (RCTs)

Two randomized, double blind, placebo controlled trials have been completed since the most recent WHO Guidelines addressing the treatment of pregnant women with PZQ. [64, 65]One randomized, controlled trial conducted in Uganda, assigned women attending a hospital-based antenatal clinic into one of four groups: placebo, albendazole, praziquantel, or praziquantel + albendazole. The study agent(s) were given during the second or third trimester

(mean gestational age 26.6 weeks).[64] This large trial did not demonstrate a significant impact of PZQ on maternal anemia or birth weight, even among the approximately 18% of women who were infected with *S. mansoni*.

A second RCT, conducted in Leyte, The Philippines, recruited only women who were infected with *S. japonicum* at the time of enrolment. Women (N=360) were treated at 12-16 weeks gestation with 60 mg/kg of Praziquantel given as a split dose over 4 hours or placebo. PZQ did not significantly impact the primary outcome, birth weight, nor other secondary outcomes including prevalence of low birth weight, prematurity, and intra-uterine growth restriction. PZQ treatment did culminate in increased maternal serum ferritin levels at 32 weeks gestation with a trend toward improved new born iron endowment. In addition, pregnant women were successfully treated as defined by parasitological cure at 22 weeks gestation. Treatment was well tolerated with reactogenicity rates similar to that observed in non-pregnant subjects. Importantly, there were no significant differences in key safety outcomes including abortion, foetal death *in utero* and congenital anomalies. [65]

Policy implications/Future Directions

Though some nations, reassured by results of RCTs, have recently adopted recommendations to include pregnant women in PZQ MDA campaigns,[64, 65] many nations still have not. [66]For example, in Zanzibar, where local guidelines did not recommend treatment of pregnant women, two of the most commonly reasons cited by individuals for not receiving PZQ during community treatment campaigns were pregnancy and breast feeding.[67] Furthermore, there is concern that even in nations that have adopted these recommendations, limited dissemination of information to schistosomiasis program managers and health care providers has led to continued exclusion. Across these nations, millions of women of reproductive age are not treated for many years during repeated cycles of pregnancy and lactation. An unfortunate implication of this creates an obvious refugia for schistosomes within the human populace ultimately facilitating environmental transmission.

Conclusions

The exclusion of two of the most vulnerable infected populations (pregnant women, PSAC) from schistosomiasis control programmes is detrimental not only to their own health present and future, but it also precludes the elimination of this parasitic disease in endemic areas. This inequality is also reflected in the research effort dedicated to these groups as shown in **Figure 2.** There is a disproportionate amount of evidence derived from other aspects of schistosomiasis in detriment of PSAC and pregnancy data, notwithstanding returned travellers. Paradigm shifts are not only needed to acknowledge light infections as pernicious to health and moving away from heavy worm burdens as the only accurate morbidity indexes. It is also indispensable to think of alternative PZQ delivery platforms to target at-risk populations that can synergise with ongoing MDA efforts. One model could include PZQ delivery at antenatal clinics and maternal-child health visits.

Some interventions that can help address these issues include education to programme managers in endemic regions that lead MDA campaigns on the safety of PZQ in pregnancy. Clinical officers and nurses in clinics can be educated on the safe delivery of PZQ in PSAC. In addition, women, who have been told for decades that they cannot be treated when pregnant or breast feeding, will likely need targeted re-education. Finally, co-authors of the Philippines RCT and regulatory program staff at the United States' (US) National Institutes of Health/National Institute of Allergy and Infectious Diseases, are collaborating with the US Federal Drug Administration to change PZQ's class designation from B to A, indicating safe use during human pregnancy as supported by well controlled studies.

Within the existing PZQ supply constraints the commitment from national control programmes has to expand its views and operate on an evidence-based agenda, without neglecting at-risk populations in need of treatment. It will take a coordinated effort between national and international agencies and strong advocacy to achieve this, but the time is right to make these changes.

Figure 2: Articles published and indexed in Pubmed in the last 10 years on schistosomiasis in pregnant women, children and preschool children.*



* MeSH search terms used: 'schistosomiasis and human' ; 'schistosomiasis and pregnancy'; 'schistosomiasis and children, not adults' and 'schistosomiasis and child, preschool not adults'.

Conflict of interest statement

The authors have no potential conflicts of interest

Acknowledgements

We warmly thank Professor Charles King for his input in the literature search. JRS is Director of COUNTDOWN which receives funding from DFID, UK.

Figure legends

Figure 1: A schematic of (**A**) prevalence by age inferred by egg-count versus serology across an endemic population (i.e. in mothers and their children's) and (**B**) visual detection of

antibodies to soluble eggs antigen (SEA) in mothers (M) and children (C) from lakeshore village on Lake Albert, Uganda. Positive (+) and negative (-) controls indicated.

Figure 2: Articles published and indexed in Pubmed in the last 10 years on schistosomiasis in pregnancy, children and preschool children.

References

1 Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223

2 King CH. It's time to dispel the myth of "asymptomatic" schistosomiasis. PLoS Negl Trop Dis 2015; 9: e0003504

3 Feasey N, Wansbrough-Jones M, Mabey DCW, Solomon AW. Neglected tropical diseases. British Medical Bulletin 2010; 93: 179-200

4 Colley DG, Bustinduy AL, Secor E, King CH. Human schistosomiasis. Lancet 2014; 383: 2253-2264

5 Ross AG, Vickers D, Olds GR, Shah SM, McManus DP. Katayama syndrome. Lancet Infect Dis 2007; 7: 218-24

6 Stothard JR, Sousa-Figuereido JC, Betson M et al. *Schistosoma mansoni* infections in young children: when are schistosome antigens in urine, eggs in stool and antibodies to eggs first detectable? PLoS Negl Trop Dis 2011; 5: e938

7 Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet 2014; 383: 2253-64

8 Bustinduy AL, Friedman JF, Kjetland EF et al. Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis. PLoS Negl Trop Dis 2016; 10: e0004946

9 Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21: 659-67

10 Wichmann D, Poppert S, Von Thien H et al. Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis. Bmc Infectious Diseases 2013; 13

11 Stothard JR, Stanton MC, Bustinduy AL et al. Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. Parasitology 2014; 141: 1947-1961

12 Organization WH. Assesing the efficacy of anthelminthic drugs against scihstosomiasis and soil-transmitted helminthiasis. Geneva: Switzerland, 2013

13 Sousa-Figueiredo JC, Betson M, Atuhaire A et al. Performance and Safety of Praziquantel for Treatment of Intestinal Schistosomiasis in Infants and Preschool Children. Plos Neglected Tropical Diseases 2012; 6

14 Stothard JR, Sousa-Figueiredo JC, Navaratnam AMD. Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. Expert Review of Anti-Infective Therapy 2013; 11: 733-752

15 Sousa-Figueiredo JC, Stanton MC, Katokele S et al. Mapping of Schistosomiasis and Soil-Transmitted Helminths in Namibia: The First Large-Scale Protocol to Formally Include Rapid Diagnostic Tests. Plos Neglected Tropical Diseases 2015; 9: 21

16 Jordan P. Epidemiology and control of schistosomiasis. British Medical Bulletin 1972; 28: 55-&

17 Bustinduy AL, Friedman JF, Kjetland EF et al. Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis. Plos Neglected Tropical Diseases 2016; 10

18 Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: let them now be treated! Trends in Parasitology 2013; 29: 197-205

19 Sousa-Figueiredo JC, Pleasant J, Day M et al. Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. International Health 2010; 2: 103-113

20 King CH. Health metrics for helminth infections. Acta Trop 2015; 141: 150-60

21 Stothard JR, Campbell SJ, Osei-Atweneboana MY et al. Towards interruption of schistosomiasis transmission in sub-Saharan Africa: Developing an appropriate environmental surveillance framework to guide and to support 'end game' interventions. Infectious Diseeases of Poverty 2017; in press

22 Seto EYW, Sousa-Figueiredo JC, Betson M et al. Patterns of intestinal schistosomiasis among mothers and young children from Lake Albert, Uganda: water contact and social networks

451 inferred from wearable global positioning system dataloggers. Geospatial Health 2012; 7: 1-
452 13
453 23 Salawu OT, Odaibo AB. Maternal schistosomiasis: a growing concern in sub-Saharan Africa.
454 Pathogens and Global Health 2014; 108: 263-270
455 24 Coltart CE, Chew A, Storrar N et al. Schistosomiasis presenting in travellers: a 15 year
456 observational study at the Hospital for Tropical Diseases, London. Trans R Soc Trop Med Hyg
457 2015; 109: 214-20
458 25 Churchill DR, Chiodini PL, McAdam K. Screening the returned traveller. British Medical Bulletin
459 1993; 49: 465-474
460 26 Rochat L, Bizzini A, Senn N et al. Acute Schistosomiasis: A Risk Underestimated by Travelers
461 and a Diagnosis Frequently Missed by General Practitioners-A Cluster Analysis of 42 Travelers.
462 Journal of Travel Medicine 2015; 22: 168-173
463 27 Carod-Artal FJ. Neurological complications of Schistosoma infection. Transactions of the Royal
464 Society of Tropical Medicine and Hygiene 2008; 102: 107-116
465 28 Schleenvoigt BT, Gajda M, Baier M et al. Placental Schistosoma haematobium infection in a
466 German returnee from Malawi. Infection 2014; 42: 1061-1064
467 29 Ben-Chetrit E, Lachish T, Morch K et al. Schistosomiasis in Pregnant Travelers: A Case Series.
468 Journal of Travel Medicine 2015; 22: 94-98
469 30 Christinet V, Lazdins-Helds JK, Stothard JR, Reinhard-Rupp J. Female genital schistosomiasis
470 (FGS): from case reports to a call for concerted action against this neglected gynaecological
471 disease. International Journal for Parasitology 2016; 46: 395-404
472 31 van Dam GJ, Xu J, Bergquist R et al. An ultra-sensitive assay targeting the circulating anodic
473 antigen for the diagnosis of Schistosoma japonicum in a low-endemic area, People's Republic
474 of China. Acta Trop 2015; 141: 190-7
475 32 Boissier J, Grech-Angelini S, Webster BL et al. Outbreak of urogenital schistosomiasis in Corsica
476 (France): an epidemiological case study. Lancet Infectious Diseases 2016; 16: 971-979
477 33 Kjetland EF, Leutscher PD, Ndhlovu PD. A review of female genital schistosomiasis. Trends
478 Parasitol 2012; 28: 58-65
479 34 Hegertun IE, Sulheim Gundersen KM, Kleppa E et al. S. haematobium as a common cause of
480 genital morbidity in girls: a cross-sectional study of children in South Africa. PLoS Negl Trop
481 Dis 2013; 7: e2104
482 35 Kjetland EF, Ndhlovu PD, Gomo E et al. Association between genital schistosomiasis and HIV
483 in rural Zimbabwean women. AIDS 2006; 20: 593-600
484 36 Downs JA, Mguta C, Kaatano GM et al. Urogenital schistosomiasis in women of reproductive
485 age in Tanzania's Lake Victoria region. Am J Trop Med Hyg 2011; 84: 364-9
486 37 Kjetland EF, Leutscher PDC, Ndhlovu PD. A review of female genital schistosomiasis. Trends in
487 Parasitology 2012; 28: 58-65
488 38 Downs JA, Kabangila R, Verweij JJ et al. Detectable urogenital schistosome DNA and cervical
489 abnormalities 6 months after single-dose praziquantel in women with Schistosoma
490 haematobium infection. Trop Med Int Health 2013; 18: 1090-6
491 39 Crompton DWT, World Health Organization. Preventive chemotherapy in human
492 helminthiasis : coordinated use of anthelminthic drugs in control interventions : a manual for
493 health professionals and programme managers. Geneva: World Health Organization, 2006
494 40 Organization WH. Investing to overcome the global impact of neglected tropical diseases.
495 Third WHO report on neglected tropical diseases. . Geneva: Switzerland, 2015
496 41 Organisation WH. Schistosomiasis: number of people treated worldwide in 2014. Wkly
497 Epidemiol Rec 2016; 91: 53-60
498 42 Hotez PJ, Engels D, Fenwick A, Savioli L. Africa is desperate for praziquantel. Lancet 2010; 376:
499 496-498
500 43 Organization WH. Schistosomiasis: Progress report 2001-2011 and strategic plan 2012-2020.
501 Geneva: Switzerland: WHO, 2013

44 Organization WH. International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026. WHO/DAP/CTD/98.5. Geneva: Switzerland: WHO, 1998

45 Stothard JR, Sousa-Figueiredo JC, Betson M et al. Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology 2011; 138: 1593-1606

46 Fenwick A, Jordan P. Schistosomiasis elimination by 2020 or 2030? International Journal for Parasitology 2016; 46: 385-388

47 Fenwick A, Webster JP, Bosque-Oliva E et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 2009; 136: 1719-1730

48 Stothard JR, Bustinduy AL, Montresor A. Preventive chemotherapy for schistosomiasis and soil-transmitted helminthiasis by cotreatment with praziquantel and albendazole. Clinical Investigation 2014; 4: 163-176

49 Bustinduy AL, Wright S, Joekes EC et al. One hundred years of neglect in paediatric schistosomiasis. Parasitology 2017: 1-11

50 Mutapi F. Changing Policy and Practice in the Control of Pediatric Schistosomiasis. Pediatrics 2015; 135: 536-544

51 Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC et al. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. Mbio 2016; 7

52 Olliaro PL, Vaillant MT, Belizario VJ et al. A Multicentre Randomized Controlled Trial of the Efficacy and Safety of Single-Dose Praziquantel at 40 mg/kg vs. 60 mg/kg for Treating Intestinal Schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. Plos Neglected Tropical Diseases 2011; 5

53 King CH. It's Time to Dispel the Myth of "Asymptomatic" Schistosomiasis. Plos Neglected Tropical Diseases 2015; 9

54 Bustinduy AL, Wright SG, Joekes EC et al. One hundred 100 years of neglect in paediatric schistosomiasis. Parasitology 2017

55 Barda B, Coulibaly JT, Hatz C, Keiser J. Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: A randomized controlled trial. PLoS Negl Trop Dis 2017; 11: e0005400

56 Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). Journal of Antimicrobial Chemotherapy 2014; 69: 863-870

57 Olliaro PL, Vaillant M, Hayes DJ, Montresor A, Chitsulo L. Practical dosing of praziquantel for schistosomiasis in preschool-aged children. Tropical Medicine & International Health 2013; 18: 1085-1089

58 Frohberg H. The toxicological profile of praziquantel in comparison to other anthelminthic drugs. Acta Leiden 1989; 57: 201-15

59 Ni YC, Shao BR, Zhan CQ et al. Mutagenic and teratogenic effects of anti-schistosomal praziquantel. Chin Med J (Engl) 1982; 95: 494-8

60 Friedman JF, Mital P, Kanzaria HK, Olds GR, Kurtis JD. Schistosomiasis and pregnancy. Trends Parasitol 2007; 23: 159-64

61 Olds GR. Administration of Praziquantel to pregnant and lactating women. Acta Trop 2003; 86: 185-95

62 WHO. Report of the WHO Informal Consultation on the use of Praziquantel during Pregnancy Lactation and Albendazole/Mebendazole in Children under 24 months. In: Organization WH, ed. Geneva, 2002

552 63 Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR. New policies for using anthelmintics
553 in high risk groups. Trends Parasitol 2002; 18: 381-2
554 64 Ndibazza J, Muhangi L, Akishule D et al. Effects of deworming during pregnancy on maternal
555 and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial. Clin Infect Dis
556 2010; 50: 531-40
557 65 Olveda RM, Acosta LP, Tallo V et al. Efficacy and safety of praziquantel for the treatment of
558 human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-
559 controlled trial. Lancet Infectious Diseases 2016; 16: 199-208
560 66 Kihara JH, Kutima HL, Ouma J et al. Urogenital schistosomiasis in women of reproductive age
561 and pregnant mothers in Kwale County, Kenya. J Helminthol 2015; 89: 105-11
562 67 Knopp S, Person B, Ame SM et al. Praziquantel coverage in schools and communities targeted
563 for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey. Parasit
564 Vectors 2016; 9: 5

565